<code id='E49C43C1C5'></code><style id='E49C43C1C5'></style>
    • <acronym id='E49C43C1C5'></acronym>
      <center id='E49C43C1C5'><center id='E49C43C1C5'><tfoot id='E49C43C1C5'></tfoot></center><abbr id='E49C43C1C5'><dir id='E49C43C1C5'><tfoot id='E49C43C1C5'></tfoot><noframes id='E49C43C1C5'>

    • <optgroup id='E49C43C1C5'><strike id='E49C43C1C5'><sup id='E49C43C1C5'></sup></strike><code id='E49C43C1C5'></code></optgroup>
        1. <b id='E49C43C1C5'><label id='E49C43C1C5'><select id='E49C43C1C5'><dt id='E49C43C1C5'><span id='E49C43C1C5'></span></dt></select></label></b><u id='E49C43C1C5'></u>
          <i id='E49C43C1C5'><strike id='E49C43C1C5'><tt id='E49C43C1C5'><pre id='E49C43C1C5'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:explore    - browse:87
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus